EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Phase 3 data expected in the second half of 2024
Subscribe To Our Newsletter & Stay Updated